Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

Sumitomo Dainippon will pay $3 billion to acquire Roivant's stakes’ in five of its “vants” encompassing women's health, urology and rare diseases, propping up its pipeline as it anticipates losing U.S. market exclusivity on antipsychotic Latuda lurasidone and discontinues pancreatic cancer candidate napabucasin.

Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) is paying Roivant Sciences GmbH (Basel, Switzerland) about half of the Japanese company’s market

Read the full 628 word article

User Sign In